Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM: FARN) (First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, is pleased to announce the appointment of Dr Juho Jalkanen to the Board of Directors as an Executive Director and Mr. Colin Bond to the Board of Directors as a Non-executive Director of...
Read more
Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM TURKU, FINLAND - The annual general meeting ("AGM") of Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) took place at BioCity in Turku, Finland, today 21 March 2025. Forty shareholders representing 42,951,148 shares and votes were represented in the meeting. The AGM approved all the proposals...
Read more
BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that one of the company's lead program; BI-1808 as monotherapy in Cutaneous T Cell Lymphoma (CTCL) will be presented at the 16th Annual T-Cell Lymphoma Forum held March 20-22, 2025 in La Jolla, California. The data,...
Read more
Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HLX22 (AC101), an anti-HER2 monoclonal antibody, for the treatment of gastric cancer. HLX22 is being developed by Shanghai Henlius Biotech, Inc. under a sublicense from AbClon, Inc., which had previously licensed the antibody from Alligator. The FDA's ODD provides incentives such as tax...
Read more
Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces a collaboration with renowned Big Data and analytics leader to enhance the development of its proprietary technology solutions designed to facilitate Rx-to-OTC switches for pharmaceutical products. The collaboration will incorporate an...
Read more
POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition of a new clinical site at Hamilton Health Sciences (HHS) in Ontario, Canada. This expansion marks a key milestone in IGC Pharma's strategy to advance IGC-AD1 toward commercialization, accelerating patient enrollment and expanding the...
Read more
BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BI-1808, a first-in-class anti-TNFR2 antibody for the treatment of T-cell Lymphoma (TCL). T-cell lymphomas include a number of...
Read more
Faron Pharmaceuticals (HEL:FARON)(AIM:FARN) Shareholders' Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected Faron Pharmaceuticals Ltd. (AIM:FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that Shareholders' Nomination Board updates its recommendation on number of Board members...
Read moreBionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) today announced that it has submitted an application to uplist from the OTC Pink to the OTCQB Venture Market. The application process involves a thorough review by OTC Markets Group, which assesses the company's financials, governance, and disclosures. Upon approval, Bionoid Pharma will be able to utilize the U.S. Securities and Exchange Commission's (SEC) modernized Rule 15c2-11 framework,...
Read more
Cortland Biomedical, a full-service biomedical textile product development partner that provides access to a full spectrum of custom engineering services, has expanded its braiding capabilities with the addition of flat braiding and round-flat-round braiding equipment. This latest investment provides Cortland Biomedical's OEM customers with access to a full suite of braiding technologies, further strengthening the company's position as a trusted...
Read more
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2024. Recent Highlights Extended its collaborations with the University of Virginia and Scripps Research through 2025; Entered into a Clinical Trial Services Agreement with PeriNess...
Read moreOndine Biomedical Inc. (LON:OBI), a global leader in light-activated antimicrobial technologies, is pleased to announce that patient recruitment has commenced in an intensive care unit (ICU) pilot study at Royal Columbian Hospital (RCH) in New Westminster, British Columbia. Treating patients in intensive care units (ICUs) with Ondine's Steriwave® nasal photodisinfection technology would significantly expand the market opportunity for Steriwave....
Read more
Moolec Science SA (NASDAQ:MLEC), a public limited liability company (société anonyme) governed by the laws of the Grand Duchy of Luxembourg, having its registered office at 17, Boulevard F.W. Raiffeisen, L-2411 Luxembourg, Grand Duchy of Luxembourg, and registered with the Luxembourg Register of Commerce and Companies (Registre de Commerce et des Sociétés de Luxembourg) under registration number B268440 ("Moolec," the "Company," "we," "us" or...
Read more
IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's Hospital in St. Petersburg, Florida as part of its ongoing Phase 2 CALMA trial evaluating IGC-AD1, the Company's lead therapeutic candidate, for the treatment of agitation in Alzheimer's dementia. IGC-AD1 is a combination therapy designed to address agitation in Alzheimer's disease. As a two-API...
Read moreBionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its financial audits for the fiscal years 2022 and 2023 by Olayinka Oyebola & Co., a PCAOB-registered firm. This milestone marks a significant step in Bionoid's commitment to financial transparency and regulatory compliance as the company continues executing its long-term growth strategy. Olayinka Oyebola & Co. has worked diligently to complete...
Read more
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric antigen receptor (CAR) T cells in a syngeneic B16 melanoma murine model of lung metastasis. The poster...
Read more
Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Quarterly sales doubled, expanding market potential exponentially SEK t Q3 24/25 Q3 23/24 May-Jan 24/25 May-Jan 23/24 Full year 23/24 Net sales 2,261 1,075 6,287 5,391 7,290 Operating profit (loss) -22,183 -27,848 -65,499 -85,355 -126,845 Profit (loss) for the period -22,816 -27,343 -66,857 -85,292 -124,823 Earnings per share, after dilution -0.23 -0.44 -0.74 -1.66 -2.14 Average number...
Read more
IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report entitled "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the...
Read more
KØBENHAVN, DK / ACCESS Newswire / March 12, 2025 / FluoGuide A/S (STO:FLUO) The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39 29 64 38 (the "Company" or "FluoGuide"), to be held on 27 March 2025 at 2.00 PM (CET) at the Company's premises, Titanhus, Titangade 9-13, meeting room - Kronos, DK-2200 Copenhagen N, Denmark. The agenda for the Annual General Meeting is as follows: 1....
Read more
UPPSALA, SE / ACCESS Newswire / March 12, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B) (FRA:9II) Today, Biovica, a leader in blood-based cancer monitoring, announces a partnership with Outcomes4Me, the developer of the leading direct-to-patient empowerment platform that provides personalized, evidence-based navigation to people diagnosed with cancer. Together, Biovica and Outcomes4Me will support post-menopausal patients with...
Read more
